发明名称 Polynucleotides for treating oncogenic viral polypeptide positive tumors
摘要 This document relates to polynucleotides encoding antigenic polypeptides to induce an immune response to oncogenic viral polypeptides. Also provided are compositions comprising polynucleotides encoding antigenic polypeptides, and methods of use. In the provided methods, the virus can be a human papilloma virus. In some embodiments, a method for killing a cell expressing a first oncogenic viral polypeptide in a subject is provided. The method includes administering to the subject a composition in an amount sufficient to initiate an immune response against the first oncogenic viral peptide, where the composition comprises a pharmaceutically acceptable carrier and a polynucleotide provided herein and the immune response is effective to cause a cytotoxic effect in the cell. In some embodiments, the polynucleotide includes a second nucleotide sequence encoding a second antigenic polypeptide. The first oncogenic viral polypeptide can be E6 and the second oncogenic viral polypeptide can be E7.
申请公布号 US9492526(B2) 申请公布日期 2016.11.15
申请号 US201314373844 申请日期 2013.01.23
申请人 Sanford Health 发明人 Lee John H.;Vermeer Daniel W.
分类号 A61K39/12;C07K14/005;C12N7/00;A61K39/00 主分类号 A61K39/12
代理机构 McDonnell Boehnen Hulbert & Berghoff LLP 代理人 McDonnell Boehnen Hulbert & Berghoff LLP
主权项 1. An isolated polynucleotide comprising at least one nucleotide sequence encoding at least two antigenic polypeptides, wherein said at least two antigenic polypeptides: (a) comprise (i) a first antigenic polypeptide comprising an amino acid sequence having at least 85% sequence identity over its length to the amino acid sequence of SEQ ID NO:2 and having a point mutation compared to SEQ ID NO:2 at each of L50, E148, T149, Q150, and L151; and (ii) a second antigenic polypeptide comprising an amino acid sequence having at least 85% sequence identity over its length to the amino acid sequence of SEQ ID NO:4 and having a point mutation compared to SEQ ID NO:4 at each of H2, C24, E46, and L67; (b) are capable of initiating an immune response to the oncogenic viral polypeptide in an immune-competent host; and (c) are non-oncogenic in the immune-competent host.
地址 Sioux Falls SD US